The development of new biomarkers for the diagnosis and prognosis of ovarian cancer may provide an opportunity for new therapies. In this study, we aimed to compare cytokines (interleukin [IL]-2, IL-5, IL-6, IL-8, IL-10 and tumour necrosis factor [TNF]-a) and nitric oxide (NO) metabolite levels in nonneoplastic tumours, benign primary ovarian tumours and malignant primary ovarian neoplasms. The secondary aim was to relate cytokine and intracystic NO metabolite levels to clinical, laboratory and pathologic characteristics for patients with primary ovarian malignancies. We evaluated 110 patients with adnexal masses. Cytokine concentrations were quantified by enzyme-linked immunosorbent assay and nitrate concentrations by enzymatic reduction of nitrite by nitrate reductase.
Introduction
The American Cancer Society estimates that approximately 22,440 women in the United States will be diagnosed with ovarian cancer in 2017, and approximately 14,080 will die from the disease [1, 2] . According to data from Globocan [3] , the estimated annual global incidence of ovarian cancer is 238,719, with 151,917 annual deaths from the disease.
Despite a vast amount of clinical and laboratory research, improvements in surgical techniques and increasing chemotherapeutic options, ovarian cancer remains the most deadly gynaecologic malignancy and a major cause cancer morbidity [4] , with most patients diagnosed at an advanced stage [5] .
Chronic inflammation is an important contributor to ovarian cancer pathogenesis, affecting all stages of cancer formation, including initiation, promotion and progression [6] . Inflammatory cells and mediators in the tumour microenvironment produce chemokines, cytokines and prostaglandins, several of which participate in oncogenesis and angiogenesis [7] through neutrophil, mast cell and macrophage recruitment [8, 9] .
The ovarian tumour microenvironment has been described as rich in proinflammatory cytokines and chemokines [10] . A Th1 to Th2 imbalance may alter proinflammatory cytokine secretion to enhance tumour progression [11] .
Nitric oxide (NO), a free radical gaseous messenger participating in several biologic functions, is generated by a family of isoenzymes through the enzymatic catalysis of essential amino acid L-arginine to L-citrulline [12] . High NO concentrations induce apoptosis, whereas low concentrations stimulate tumour growth through angiogenesis [13] . Thus, NO produces variable, complex effects, sometimes contributing to tumour regression and sometimes to progression.
Development of new ovarian cancer biomarkers to aid diagnosis and determine prognosis could also lead to new therapies. Intracystic fluid concentrations of IL-2, IL-5, IL-6, IL-8, IL-10, TNF-a and NO metabolites likely differ for primary benign ovarian and malignant ovarian tumours, and these differences may affect disease prognosis.
The primary objective of this study was to compare intracystic fluid cytokine (IL-2, IL-5, IL-6, IL-8, IL-10 and TNF-a) and NO metabolite levels among non-neoplastic tumours, benign primary ovarian neoplasms and malignant primary ovarian neoplasms. The secondary aim was to determine the association between intracystic cytokine and NO metabolite levels and clinical, laboratory and pathologic characteristics for patients with primary ovarian malignancy.
Material and methods
Patients. A total of 110 patients with adnexal masses were evaluated at the Pelvic Mass Ambulatory of the Discipline of Gynecology and Obstetrics/Oncology Research Institute (IPON) of the Federal University of the Triângulo Mineiro (UFTM). All patients underwent exploratory laparotomy [14, 15] from May 2009 to December 2016 and were subsequently diagnosed with a neoplastic or non-neoplastic ovarian tumour.
The inclusion criterion was a post-operative diagnosis of non-neoplastic ovarian tumour or ovarian neoplasm based on anatomic pathology. Patients were excluded if they had adnexal pedicle torsion, cyst rupture during surgery, ovarian tumour metastasis, presurgical antineoplastic treatment, tumour relapse, endometrioma or systemic autoimmune disease.
Patients were placed into three groups based on anatomic pathologic classification of their ovarian neoplasm: non-neoplastic tumour (n = 17); benign neoplasm (n = 71) or malignant neoplasm (n = 22 Neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) values were obtained by dividing the absolute number of neutrophils and platelet counts, respectively, by the absolute number of lymphocytes. A cut-off value of 2.6 was used for NLR [19] and 300 for PLR [20] .
To evaluate DFS, patients were divided into groups with DFS less than 36 months and DFS greater than 36 months. Overall survival OS was evaluated by dividing patients into groups based on an OS less than 60 months or OS greater than 60 months. Patients who were lost to follow-up, or for whom data were incomplete, were excluded from these analyses.
The study was reviewed and approved by the Research Ethics Committee of the Federal University of Triângulo Mineiro (protocol number 1408). Written informed consent was obtained from each patient or from his or her relatives.
Methods. Intracystic fluid collection. All ovarian tumours were punctured immediately after cyst excision to obtain 20 ml of intracystic contents by slow aspiration. Specimens were then centrifuged at 189 g for 10 minutes, and the resulting supernatant was collected in 300 ll aliquots and stored in a freezer at À20°C until cytokine and NO metabolite measurements were performed [21] .
Enzyme-linked immunosorbent assay to determine cytokine levels. IL-2, IL-5, IL-6, IL-8, IL-10 and TNF-a concentrations were quantified by enzyme-linked immunosorbent assay (ELISA). To capture antibodies, 96-well plates were coated with 50 ll per well of antibody specific for each cytokine then diluted (1-3 lg/ll) in binding buffer solution (Na 2 HPO 4 ). Plates were incubated for 16-24 h at 4°C. Results were expressed in pictograms for each cytokine, by level per millilitre of intracystic fluid supernatant [22] .
Colorimetric assay to determine nitric oxide metabolites. Intracystic fluid nitrate levels were quantified by enzymatic reduction of nitrite by nitrate reductase, as described by Schmidt et al. First, 40 ll samples were incubated with 0.1 M potassium phosphate at a pH of 7.5, 1 mM nicotinamide phosphate adenine dinucleotide, 10 mM flavin adenine dinucleotide and 4 IU nitrate reductase/ml for 20 h at 37°C. A standard nitrate curve was created by incubating sodium nitrate (10-200 lM) with reductase buffer. The total amount of NO metabolites in the intracystic fluid samples was then determined by colorimetric assay based on the Griess reaction [23] . The absorbance was measured at 546 nm, and results were expressed as micromol (lM) of nitrite (NO 2 ).
Statistical analysis. Data were analysed using GRAPH-PAD PRISM software 6 (La Jolla, CA, USA). The D'Agostino and Pearson test showed a non-normal data distributed; thus, results were expressed as medians and percentiles (10th, 25th, 75th and 90th). Results for non-paired groups (non-neoplastic tumours, benign neoplasms and malignant neoplasms) were analysed by Kruskal-Wallis test, with Dunn's post hoc test. Prognostic factor evaluation was performed by Mann-Whitney test. A P value less than 0.05 was considered statistically significant.
Results
Of the 110 patients in this study, 17 had non-neoplastic tumours, 71 had benign ovarian tumours and 22 had malignant ovarian tumours. Patient median age varied by tumour type: those with non-neoplastic tumours had a median age of 47 (range, 34-87 years), benign ovarian neoplasms a median age of 49 (range, 11-77 years) and malignant ovarian neoplasms a median age of 58 (range, 34-82 years) ( Table 1 ). Nine patients (40.9%) with malignant ovarian tumours died; there were no deaths among those with non-neoplastic or benign ovarian tumours.
Histologic diagnosis showed that non-neoplastic ovarian tumours were comprised of eight (47.1%) simple cysts, four (23.5%) theca lutein cysts, three (17.6%) follicular cysts, one (5.9%) corpus luteum haemorrhagic cyst and one (5.9%) inclusion cyst. Of the benign ovarian tumours, 31 (43.6%) were serous cystadenomas, 20 (28.2%) mucinous cystadenomas and 20 (28.2%) mature cystic teratomas. Malignant ovarian tumours consisted of six (27.3%) serous cystadenocarcinomas, six (27.3%) borderline mucinous tumours, four (18.2%) granulosa cell tumours, two (9.1%) clear-cell adenocarcinomas, two (9.1%) borderline serous tumours, one (4.5%) immature teratoma and one (4.5%) endometrioid adenocarcinoma.
Of the 22 malignant ovarian tumours, there were 10 (45.5%) IA, one (4.5%) IB, four (18.2%) IC, one (4.5%) IIA, one (4.5%) IIIA, two (9.1%) IIIB and three (13.7%) IIIC. Histologic grade frequencies for these malignant tumours were 15 (68.2%) grade 1, six (27.3%) grade 2 and one grade 3 (4.5%). We found 12 (70.6%) type 1 tumours and five (29.4%) type 2 tumours. Figure 1 shows the difference in cytokine and nitric oxide metabolite levels among non-neoplastic tumours, benign ovarian neoplasms and malignant ovarian neoplasms. Levels of IL-6, IL-8 and NO were higher in the malignant neoplasm group compared to the benign neoplasm group (Figure 1C, D and G) , but there were no differences for other measured cytokines. Figure 2 shows the association between cytokine level and pathologic and clinical prognostic factors for ovarian malignancies. IL-2 levels were higher in histologic grade 1 tumours compared to histologic grade 2 and 3 tumours (Figure 2A ). Patients with DFS less than 36 months ( Figure 2B ) had higher intracystic fluid IL-8 levels. Those with type 2 carcinogenesis had higher TNF-a levels compared to those with type 1 carcinogenesis ( Figure 2C ). Other cytokines and nitric oxide levels did not differ with respect to tumour prognostic factors. Figure 3 shows the relationship between cytokines and nitric oxide and laboratory prognostic factors for patients with malignant ovarian neoplasms. Patients with anaemia had higher IL-6 levels compared to those with haemoglobin levels greater than 12 g/dl ( Figure 3A) . IL-8 levels were higher in patients with an NLR greater than 2.6 compared to those with an NLR less than 2.6 ( Figure 3B ). Lower IL-10 levels were found in patients with a CA 19-9 level greater than 35 U/ml compared to those with a CA 19-9 level less than 35 U/ml ( Figure 3C ). Furthermore, TNF-a was expressed at higher concentrations in patients with a PLR less than 300 compared to those with a PLR greater than 300 ( Figure 3D ). Lastly, NO levels were higher among patients with an NLR less than 2.6 ( Figure 3E ) and those with a CA 19-9 level greater than 35 U/ml ( Figure 3F ).
Discussion
The highly organized molecular and cellular immune microenvironment of tumour tissues is comprised of different cell types and soluble molecules including cytokines, which may exert pro-tumour or antitumour effects, depending on context [24, 25] .
IL-2, a pleiotropic cytokine that stimulates proliferation and activation of natural killer cells, is also the main T cell stimulator that induces differentiation of regulatory T cells and mediates cell death [26] . In malignant ovarian neoplasms, increased IL-2 receptor concentrations are associated with more advanced disease and predict recurrence [27] . Despite this role, a previous study showed no difference in intracystic IL-2 levels between benign and malignant neoplasms [28] . Likewise, our study showed no difference in IL-2 expression in intracystic fluid among non-neoplastic tumours, primary benign ovarian neoplasms or primary malignant ovarian neoplasms. Notably, among patients with primary ovarian malignancies, IL-2 expression was higher in histologic grade 1 tumours compared to grade 2 or 3 tumours. This difference suggests a welldifferentiated Th1 immune response in tumours.
High serum levels of IL-5, which is secreted by helper CD4+ T cells, have been associated with high histologic grade and advanced disease [29] , suggesting that it is a poor prognostic factor. However, IL-5 concentrations did not differ between groups in our study. IL-6, a glycoprotein whose production is mediated by other cytokines such as TNF-a, serves as an important inflammatory marker. Evidence shows that IL-6 plays a significant role in ovarian cancer pathophysiology as one of the major immunoregulatory cytokines present in the tumour microenvironment. IL-6 creates an immunosuppressive network that protects the tumour from the immune system and assists in the growth and progression of disease [30] [31] [32] [33] . In our study, IL-6 levels were higher in the malignant ovarian neoplasm group compared to the benign ovarian neoplasm group. A previous study showed a similar result to ours, demonstrating that multiple ovarian cancer cell lines and primary ovarian tumour cultures produce and secrete IL-6 [34] . Another study demonstrated a correlation between IL-6 in intracystic fluid and ovarian malignancy [28] . Additionally, elevated intracystic fluid levels of IL-6 were associated with resistance to chemotherapeutic drugs and increased disease recurrence in ovarian cancer [35] .
Qin et al. [36] demonstrated lower haemoglobin concentrations in patients with ovarian cancer compared to healthy controls. Inflammatory factors may affect iron metabolism and inhibit erythropoietin expression and erythrocyte maturation. Haemoglobin level has been shown to be associated with prognosis in ovarian borderline tumours [37] . In this study, IL-6 levels were higher in patients with anaemia.
IL-8 is secreted by mesothelial cells, endothelial cells, neutrophils and tumour cells [38] . This pro-angiogenic cytokine, found in several types of human neoplasms [39] , is associated with proliferation, angiogenic potential, adhesion and tumour invasion in ovarian cancer [40] . IL-8/CXCL-8 expression has been described as a potential biomarker of ovarian cancer [41] . Polymorphisms in cytokine genes have been associated with increased inflammation and cytokine production, as well as increased cancer risk [42] . Single nucleotide polymorphisms at the À251 position of the IL-8 promoter region have been The values were expressed in medians and percentiles (10%, 25%, 75% and 90%) (Mann Whitney test). There was higher IL-2 levels in tumours with histological grade 1 when compared to the group of tumours with histological grades 2 and 3 (*P = 0.0112). IL-8 levels were higher in patients with disease-free survival (DFS) less than 36 months (**P = 0.0288). TNF-a levels were higher in tumours with type 2 carcinogenesis model compared to type 1 ( # P = 0.0364).
Scandinavian Journal of Immunology, 2017, 86, 462-470 Figure 3 Association of cytokines and nitric oxide with laboratory prognostic factors in malignant ovarian neoplasms. The values were expressed in medians and percentiles (10%, 25%, 75% and 90%) (Mann Whitney test). Higher IL-6 levels were found in patients with anaemia compared to haemoglobin greater than 12 g/dl (*P = 0.0232). IL-8 levels were higher in patients with the neutrophil/lymphocyte ratio (NLR) ˃2.6 compared to NLR less than 2.6 (**P = 0.0443). Higher IL-10 levels were found in patients with CA19.9 less than 35 U/ml compared to CA19.9 greater than 35 U/ml ( # P = 0.0019). TNF-a was expressed at higher concentrations in patients with a platelet/lymphocyte ratio (PLR) less than 300 compared to those with a PLR greater than 300 ( ## P = 0.0420). NO levels were higher in patients with NLR less than 2.6 ( ............................................................................................................................................................ ... associated with increased activity [43] . The IL-8 polymorphism may confer a higher risk of developing some types of cancer, including ovarian cancer [44] , gastric cancer [45] and breast cancer [46] . Additionally, the polymorphism may be associated with poor prognosis in renal cell carcinoma [47] , cervical cancer [48] and breast cancer [46] .
In our study, intracystic IL-8 levels were higher in malignant neoplasms compared to benign neoplasms. With respect to prognosis, higher IL-8 levels were associated with DFS less than 36 months and an NLR greater than 2.6, suggesting a worse prognosis. In ovarian cancer, the IL-8 polymorphism has been associated with lower response rates to cyclophosphamide and bevacizumab [49] . Additionally, IL-8 levels have been detected at higher levels in cyst fluid from malignant ovarian neoplasms than benign tumours [28, 50] . Higher IL-8 levels have also been associated with lower overall survival [28] .
Although the role of IL-10 in cancer has been studied extensively, the exact relationship with tumours is unknown and its immune role in cancer is controversial. Our examination of IL-10 levels in intracystic fluid showed no difference between groups. However, higher IL-10 levels were found in patients with normal CA 19-9 levels.
TNF-a is altered in malignant ovarian tumours, with several studies showing associations between inflammation and ovarian tumourigenesis. Thus, TNF-a may play an important role in modulating tumour invasion, angiogenesis and metastasis [51, 52] .
Our results showed no difference in TNF-a levels between groups. This finding is consistent with those of Nowak et al., [53] who evaluated cytokines from serum, ascitic fluid and intracystic fluid associated with ovarian tumours. We did find, however, that TNF-a levels were increased in tumours with type 2 carcinogenesis (P = 0.0364) and patients with PLR less than 300 (P = 0.042). Type 2 ovarian tumours are more aggressive and genetically unstable [18] . TNF can have antitumour or pro-tumour effects when acting via TNFR1 or TNFR2 [51] . High concentrations of soluble TNF-R may inhibit TNF activity and allow tumours to avoid the destructive effects of TNF-a [54] . TNFR2, a potent immunosuppressor, is abnormally abundant in human tumours and promotes the growth of colon cancer, multiple myeloma, renal cell carcinoma, Hodgkin's lymphoma and ovarian cancer [55] . Its expression is limited in the immune system and is induced by IL-2. Therefore, it is expected that TNFR2 will be more highly expressed in ovarian tumours with type 2 carcinogenesis because the histologic subtypes belonging to this group are more aggressive.
NO is a gas molecule generated by tumour, stromal and endothelial cells that serves diverse roles in cancer biology. The concentration of NO may promote or inhibit neoplastic transformation, tumour progression and metastasis [56] [57] [58] . Low NO levels (less than 100 nM) promote tumour progression by inducing cell proliferation, migration, invasion and angiogenesis (through vascular endothelial growth factor secretion). In contrast, high NO levels (greater than 400 nM) induce a cytostatic/cytotoxic effect that leads to tumour regression, tumour death and inhibition of metastasis [58] [59] [60] [61] [62] . The seemingly contradictory roles of NO have been attributed to factors such as differences in NOS enzyme isoform, expression level, cell line and tumour tissue heterogeneity [63] . In this study, NO metabolite levels were not related to clinical prognostic factors among patients with ovarian malignancy. However, NO metabolite levels were related to laboratory prognostic factors of NLR less than 2.6 and elevated CA 19-9 levels. This relationship may be explained by the protective role of NO in ovarian cancer, as NLR less than 2.6 is associated with a better prognosis. CA 19-9 is often higher in mucinous and endometrioid carcinomas [64] ; thus, the increased NO level found may reflect our inclusion of a large number of patients with mucinous type tumours.
This study has some limitations, including the small number of patients with malignant neoplasms and the heterogeneity of the neoplasms. Newer studies with larger patient numbers are needed to clarify the prognostic role of cytokines. It is important to understand that multiple tumour sites in a single patient have different immunologic microenvironments. Increased heterogeneity at these sites may reflect important differences in stromal biology and intrinsic inflammatory response [65] .
Conclusion
Despite the small sample size, we found higher IL-6, IL-8 and NO levels in the intracystic fluid of patients with malignant neoplasms compared to benign neoplasms. Furthermore, higher intracystic IL-6 and IL-8 levels were associated with worse prognosis in patients with ovarian cancer. Thus, these cytokines may represent potential diagnostic and prognostic markers for ovarian neoplasms (Figure 4 ).
Further studies with on a larger group of patients are needed to confirm the role of cytokines in prognosis, treatment and future target therapies.
